- IgG1K human monoclonal antibody targetting CD38
- Indications include multiple myeloma
- Adverse effects include hypertension (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis
- Risk of infections, including CMV, HSV, and possible hepatitis B
